Cargando…

Escalation strategies for combination therapy Phase I trials

Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose that does not cause an unacceptable amount of toxicity in the patients. In trials of combination therapies, however, many different dose combinations may have a similar probability of causing a dose-lim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sweeting, Michael J, Mander, Adrian P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2012
Materias:	Main Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573644/ https://www.ncbi.nlm.nih.gov/pubmed/22411472 http://dx.doi.org/10.1002/pst.1497

Ejemplares similares

Do single‐arm trials have a role in drug development plans incorporating randomised trials?
por: Grayling, Michael J., et al.
Publicado: (2015)

Dose‐escalation strategies which use subgroup information
por: Cotterill, Amy, et al.
Publicado: (2018)

A product of independent beta probabilities dose escalation design for dual-agent phase I trials
por: Mander, Adrian P, et al.
Publicado: (2015)

Toxicity‐dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
por: Wheeler, Graham M., et al.
Publicado: (2017)

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials
por: Wheeler, Graham, et al.
Publicado: (2015)

A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods
por: Bennett, Maxine, et al.
Publicado: (2021)

A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials
por: Bowden, J, et al.
Publicado: (2014)

An optimal stratified Simon two‐stage design
por: Parashar, Deepak, et al.
Publicado: (2016)

Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials
por: Meyer, Elias Laurin, et al.
Publicado: (2022)

SCI: A Bayesian adaptive phase I/II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials
por: Zhang, Yifei, et al.
Publicado: (2022)

Misspecification of at‐risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation
por: Law, M., et al.
Publicado: (2016)

CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies
por: Hatayama, Tomoyoshi, et al.
Publicado: (2022)

A confidence function‐based posterior probability design for phase II cancer trials
por: Shan, Minghua
Publicado: (2020)

Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data
por: Kunz, Cornelia Ursula, et al.
Publicado: (2014)

HOW TO HARNESS NEW IMMUNOTHERAPIES WITH COMBINATION STRATEGIES?
por: Einsele, H.
Publicado: (2023)

Practical and robust test for comparing binomial proportions in the randomized phase II setting
por: Attwood, Kristopher, et al.
Publicado: (2021)

Imputation of missing covariate in randomized controlled trials with a continuous outcome: Scoping review and new results
por: Kayembe, Mutamba T., et al.
Publicado: (2020)

AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
por: Wheeler, Graham M., et al.
Publicado: (2016)

Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration
por: Wheeler, Graham M., et al.
Publicado: (2016)

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing
por: Best, Nicky, et al.
Publicado: (2021)

Blinded continuous monitoring in clinical trials with recurrent event endpoints
por: Friede, Tim, et al.
Publicado: (2018)

A critical review of graphics for subgroup analyses in clinical trials
por: Ballarini, Nicolás M., et al.
Publicado: (2020)

Should the two‐trial paradigm still be the gold standard in drug assessment?
por: Zhan, Stella Jinran, et al.
Publicado: (2022)

Optimal composite scores for longitudinal clinical trials under the linear mixed effects model
por: Ard, M. Colin, et al.
Publicado: (2015)

Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior
por: Qi, Hongchao, et al.
Publicado: (2022)

Prior distributions for variance parameters in a sparse‐event meta‐analysis of a few small trials
por: Pateras, Konstantinos, et al.
Publicado: (2020)

On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies
por: Unkel, Steffen, et al.
Publicado: (2018)

A compassionate imagery intervention for patients with persecutory delusions
por: Forkert, Ava, et al.
Publicado: (2022)

Cognitive appraisals of dissociation in psychosis: a new brief measure
por: Černis, Emma, et al.
Publicado: (2021)

Are young people with primary social anxiety disorder less likely to recover following generic CBT compared to young people with other primary anxiety disorders? A systematic review and meta-analysis
por: Evans, Rachel, et al.
Publicado: (2021)

Understanding agoraphobic avoidance: the development of the Oxford Cognitions and Defences Questionnaire (O-CDQ)
por: Rosebrock, Laina, et al.
Publicado: (2022)

Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols
por: Häckl, Sebastian, et al.
Publicado: (2019)

Management strategies in heart failure with preserved ejection fraction
por: Wintrich, Jan, et al.
Publicado: (2022)

Potential impact of COVID‐19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA‐TICS study
por: Lasch, Florian, et al.
Publicado: (2021)

Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
por: Schernthaner, G., et al.
Publicado: (2016)

Treatment options in myocarditis and inflammatory cardiomyopathy: Focus on i. v. immunoglobulins
por: Maisch, B., et al.
Publicado: (2018)

THE PARADOXICAL TEXT `ON THE HEART', Part I
por: Lonie, I. M.
Publicado: (1973)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Adopting AI: how familiarity breeds both trust and contempt
por: Horowitz, Michael C., et al.
Publicado: (2023)

Reference‐based sensitivity analysis for time‐to‐event data
por: Atkinson, Andrew, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3s3sa1rf3u0oh38tkckk0s3962